Clinical validation
Proving in people that a drug works and is safe.
capabilityEmerging Open on the map →
Facts
- Lane
- Science and health
- Wave
- 3 of 12 (build order, not a date)
- Needs
- 0 boxes all the way back through hard links
- Unlocks
- 2 boxes downstream through hard links
- Leverage
- 0.4 points · stands in the way of 2 of 53 stages · rank 21 of 57
- Cluster
- Science and medicine
Evidence as of October 2026
Biology sets the clock. Insilico’s rentosertib is in phase III, with initial results expected around the end of 2029.
Around it
Needs · 0
Nothing beyond the detail list. It can start at any time.
Unlocks · 1
Openings researchers' judgement, October 2026 scouting
Startup room 58/100 · rank 14 of 124 Research room 38/100 · rank 95 of 124
- Depth
- deep
- Players
- ConcertAI; Medable; WCG; Paradigm Health ($78m B); Formation Bio ($372m D); Biorce ($52.5m A); Unlearn ($50m C)
- Wedge
- Decision optimisation of trial design and enrollment schedules (operations research), or independent benchmarking of trial-AI vendor claims; sponsor-side recruitment SaaS is crowded. startup